| Ytd | 37.63% | |
| 1y | 65.82% |
| Open | 36.76 | Prev Close | 36.90 | Low | 35.77 | High | 38.66 | Mkt Cap | 1.79B |
| Vol | 349.48K | Avg Vol | 390.47K | EPS | -0.56 | P/E | N/A | Forward P/E | -19.77 |
| Beta | 2.29 | Short Ratio | 8.64 | Inst. Own | 99.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 39.33 | 200-d Avg | 31.06 | 1yr Est | 54.22 |
SEPN News
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
Jones Trading analyst Catherine Novack maintains Septerna (NASDAQ:SEPN) with a Buy and raises the
Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and raises the pr
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.29) per share which beat the analyst consens
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and lowers the pr
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
Raymond James analyst Martin Auster maintains Septerna (NASDAQ:SEPN) with a Strong Buy and raises
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G prote
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
